Cargando…
Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma
WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434124/ https://www.ncbi.nlm.nih.gov/pubmed/36059638 http://dx.doi.org/10.3389/fonc.2022.967159 |
_version_ | 1784780799669698560 |
---|---|
author | Ye, Zhang Zhang, Shenqi Cai, Jiayang Ye, Liguo Gao, Lun Wang, Yixuan Tong, Shiao Sun, Qian Wu, Yu Xiong, Xiaoxing Chen, Qianxue |
author_facet | Ye, Zhang Zhang, Shenqi Cai, Jiayang Ye, Liguo Gao, Lun Wang, Yixuan Tong, Shiao Sun, Qian Wu, Yu Xiong, Xiaoxing Chen, Qianxue |
author_sort | Ye, Zhang |
collection | PubMed |
description | WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis, a novel programmed death pathway, is closely related to the inhibition of the TCA cycle. In our study, eight of ten cuproptosis-related genes (CRGs) were found to be differentially expressed between normal and WHO 2/3 glioma tissues. Through the LASSO algorithm, the cuproptosis-associated risk signatures (CARSs) were constructed, which can effectively predict the prognosis of WHO 2/3 glioma patients and are closely related to clinicopathological features. We analyzed the relationship between risk score and immune cell infiltration through Xcell, ssGSEA, TIMER database, and immune checkpoint molecules. In addition, the relationship between risk score and chemotherapeutic drug sensitivity was also investigated. The prognosis-related independent risk factors FDX1 and CDKN2A identified from CARSs are considered potential prognostic biomarkers for WHO 2/3 glioma. The clinical prognosis model based on cuproptosis is expected to provide an effective reference for the diagnosis and treatment of clinical WHO 2/3 glioma patients. |
format | Online Article Text |
id | pubmed-9434124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94341242022-09-02 Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma Ye, Zhang Zhang, Shenqi Cai, Jiayang Ye, Liguo Gao, Lun Wang, Yixuan Tong, Shiao Sun, Qian Wu, Yu Xiong, Xiaoxing Chen, Qianxue Front Oncol Oncology WHO 2/3 glioma is a common intracranial tumor that seriously affects the quality of life and survival time of patients. Previous studies have shown that the tricarboxylic acid (TCA) cycle is closely related to the occurrence and development of glioma, while recent studies have shown that cuproptosis, a novel programmed death pathway, is closely related to the inhibition of the TCA cycle. In our study, eight of ten cuproptosis-related genes (CRGs) were found to be differentially expressed between normal and WHO 2/3 glioma tissues. Through the LASSO algorithm, the cuproptosis-associated risk signatures (CARSs) were constructed, which can effectively predict the prognosis of WHO 2/3 glioma patients and are closely related to clinicopathological features. We analyzed the relationship between risk score and immune cell infiltration through Xcell, ssGSEA, TIMER database, and immune checkpoint molecules. In addition, the relationship between risk score and chemotherapeutic drug sensitivity was also investigated. The prognosis-related independent risk factors FDX1 and CDKN2A identified from CARSs are considered potential prognostic biomarkers for WHO 2/3 glioma. The clinical prognosis model based on cuproptosis is expected to provide an effective reference for the diagnosis and treatment of clinical WHO 2/3 glioma patients. Frontiers Media S.A. 2022-08-18 /pmc/articles/PMC9434124/ /pubmed/36059638 http://dx.doi.org/10.3389/fonc.2022.967159 Text en Copyright © 2022 Ye, Zhang, Cai, Ye, Gao, Wang, Tong, Sun, Wu, Xiong and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ye, Zhang Zhang, Shenqi Cai, Jiayang Ye, Liguo Gao, Lun Wang, Yixuan Tong, Shiao Sun, Qian Wu, Yu Xiong, Xiaoxing Chen, Qianxue Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title | Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title_full | Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title_fullStr | Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title_full_unstemmed | Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title_short | Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma |
title_sort | development and validation of cuproptosis-associated prognostic signatures in who 2/3 glioma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434124/ https://www.ncbi.nlm.nih.gov/pubmed/36059638 http://dx.doi.org/10.3389/fonc.2022.967159 |
work_keys_str_mv | AT yezhang developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT zhangshenqi developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT caijiayang developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT yeliguo developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT gaolun developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT wangyixuan developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT tongshiao developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT sunqian developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT wuyu developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT xiongxiaoxing developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma AT chenqianxue developmentandvalidationofcuproptosisassociatedprognosticsignaturesinwho23glioma |